Posts tagged Eli Lilly
Chi-Med initiates fruquintinib clinical trial in U.S.

Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, that has met its primary endpoint in several Phase 2 and 3 clinical trials in China for the treatment of colorectal, lung and gastric cancers.

Read More
Mackie starts Promis at speculative buy

Mackie Research Capital initiated coverage of Promis Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents, saying the company has a promising new path to target Alzheimer’s disease (AD). The stock closed at 25 cents on Sept. 18.

Read More
IntelGenx gets oral film exclusivity for tadalafil ED dosing patent

IntelGenx (OTCQX:IGXT; TSXV:IGX) announced that Eli Lilly granted IntelGenx’s VersaFilm an exclusive license for a tadalafil film product under its 6,943,166 erectile dysfunction (ED) dosing patent. Any exclusivity associated with the tadalafil compound patent expiring is not affected by this agreement.  

Read More
Leerink downgrades Adocia to market perform

Leerink downgraded Adocia (NXT PA:ADOC.FP) to “market perform” and slashed its price target to €15.00 from €82.00 after Eli Lilly terminated its collaboration for Adocia’s ultra-fast insulin product, BioChaperone Lispro.

Read More
IntelGenx to license tadalafil patent from Lilly

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has signed a binding term sheet to license Eli Lilly's tadalafil dosing patent. Any exclusivity associated with the tadalafil compound patent is not affected by the agreement.

Read More
Merus Labs appoints two senior executives

Merus Labs International (NASDAQ:MSLI; TSX:MSL) has appointed two key additions to its executive leadership team, effective July 1.

Dr. Michael Bumby was named CFO, succeeding Andrew Patient, who has decided to leave the company to pursue other opportunities. Mr. Patient will remain with Merus Labs for a period of time to ensure a smooth transition.

Read More
Transition Therapeutics begins Phase 2 SARM study

Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701.

The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue/low vitality, and physical dysfunction in men who have undergone radical prostatectomy for organ-localized prostate cancer.

Read More
Transition Therapeutics reports TT401 trial results

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes.

TT401 is a once-weekly administered oxyntomodulin analog, with dual GLP-1 and glucagon agonist activity. TT401 development collaborator, Eli Lilly, performed the Phase 2 study, enrolling 420 Type 2 diabetes subjects into a 24-week study, consisting of a 12-week randomized blinded stage followed by a 12-week open-label stage.

Read More